Young David 4
4 · Processa Pharmaceuticals, Inc. · Filed Apr 12, 2024
Insider Transaction Report
Form 4
Young David
DirectorPres. Research & Development
Transactions
- Exercise/Conversion
Common Stock
2024-01-01+1,675→ 81,062 total - Tax Payment
Common Stock
2024-01-01$2.79/sh−518$1,445→ 80,544 total - Exercise/Conversion
Restricted Stock Units
2024-01-01−1,675→ 19,333 totalExercise: $0.00→ Common Stock (1,675 underlying)
Holdings
- 10,786(indirect: By Family Entities)
Common Stock
- 18,544(indirect: By LLC)
Common Stock
- 30,985(indirect: By Trust)
Common Stock
Footnotes (2)
- [F1]Distribution of vested restricted shares.
- [F2]Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.